Iconic Therapeutics is using Zymelink Tech for first ADC

Zymeworks Zymelink technology has been showing some good results in preclinical modeling, and pairing that with a suite of bad news around the PBD based payloads, it makes sense to move forward with this type of a collaboration.

Iconic is going after Tissue Factor targets in oncology, and their molecule ICON-2 is their first ADC product expected to head to the clinic.

Zymeworks is starting to make some waves.  Is this a company to keep an eye on?

Zymeworks Enters its First ZymeLink™ Antibody-Drug Conjugate Platform Licensing Agreement with Iconic Therapeutics